Back

Liminatus Pharma Announces $500 Million Expansion into Cryptocurrency with New Subsidiary

Liminatus Pharma’s new subsidiary, 'American BNB Strategy,' aims to raise $500 million for strategic investments in BNB, marking a notable shift into digital assets.

BNB

Summary

Liminatus Pharma, Inc. has announced its entry into the cryptocurrency and blockchain sector through a new subsidiary called 'American BNB Strategy.' The company plans to raise and deploy up to $500 million for long-term investments in BNB, while continuing its commitment to cancer treatment development. This strategic move is designed to enhance shareholder value and support long-term growth.

Terms & Concepts
  • BNB: BNB is the native cryptocurrency of the Binance exchange, used for trading fee discounts and various applications within the Binance ecosystem.
  • blockchain: A decentralized digital ledger technology that records transactions across many computers securely and transparently.
  • shareholder value: The financial worth that shareholders derive from their investment in a company, often measured through stock price appreciation and dividends.